On June 4, 2021 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported that positive Phase 1 testing data was presented at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting June 4, 2021 (Press release, AIkido Pharma, JUN 4, 2021, View Source [SID1234583606]). The poster presentation of the data was by Dr. Scott Tagawa, a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member. The full presentation is available at: View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights from the presentation include:
Declining PSA levels in treated patients
Declining circulating tumor cell (CTC) count in treated patients
Actinium-225 radiolabeled J591 well-tolerated with preliminary evidence of efficacy in a heavily pre-treated patient population
Actinium-225 radiolabeled J591 safe at tested dosage
Phase 2 trial underway
Neal Shore, MD, FACS a well-known key opinion leader in prostate cancer research, Medical Director for the Carolina Urologic Research Center and recent addition to the Company’s Advisory Board, stated, "The Phase I trial results of the 225Ac-J591 antibody for these advanced prostate cancer patients, who had extensive tumor burden as well as having experienced numerous life prolonging therapies, are impressive, both from a response and safety standpoint. PSA declines and CTC responses were clearly evident. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. The unique properties of 225Ac-J591 suggest it as a very promising candidate for combination treatment with beta emitters, whereby the synergy of therapeutic isotope combination and broader tumor effect would have the potential to further shape theragnostic platforms."
Full ASCO (Free ASCO Whitepaper) Presentation Details:
Title: "Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC)"
Tract: Genitourinary Cancer—Prostate, Testicular, and Penile
Presenter: Dr. Scott Tagawa MD, MS, FACP
Abstract Number: 5015
Date and Time: Available Starting June 4, 2021, 9:00 am (EST)
The Abstract from this study has been released on the ASCO (Free ASCO Whitepaper) Annual Meeting website (View Source). Clinical trial information: NCT03276572 (View Source )
The full ASCO (Free ASCO Whitepaper) meeting program is available at: www.asco.org